BamSEC and AlphaSense Join Forces
Learn More

Poseida Therapeutics Inc.

NASDAQ: PSTX    
Share price (12/20/24): $9.45    
Market cap (12/20/24): $921 million
Search in Documents
Key Exhibits
External Links

Plans of Reorganization, Merger, Acquisition or Similar Filter

EX-2.1
from 8-K 137 pages Agreement and Plan of Merger Among: Roche Holdings, Inc., a Delaware Corporation, Blue Giant Acquisition Corp., a Delaware Corporation, and Poseida Therapeutics, Inc., a Delaware Corporation Dated as of November 25, 2024
12/34/56
EX-2.1
from S-1 100 pages Agreement and Plan of Merger and Reorganization by and Among Poseida Therapeutics Inc., Hermes Merger Sub I, Inc., Hermes Merger Sub II, LLC, Vindico Nanobiotechnology, Inc. and Christopher Young as Stockholders’ Representative October 10, 2016
12/34/56
EX-2.1
from DRS 100 pages Agreement and Plan of Merger and Reorganization by and Among Poseida Therapeutics Inc., Hermes Merger Sub I, Inc., Hermes Merger Sub II, LLC, Vindico Nanobiotechnology, Inc. and Christopher Young as Stockholders’ Representative October 10, 2016
12/34/56
EX-2.2
from S-1 100 pages Agreement and Plan of Merger and Reorganization by and Among Poseida Therapeutics Inc., Hermes Merger Sub I, Inc., Hermes Merger Sub II, LLC, Vindico Nanobiotechnology, Inc. and Christopher Young as Stockholders’ Representative October 10, 2016
12/34/56
EX-2.1
from S-1 22 pages Asset Contribution Agreement
12/34/56
EX-2.2
from DRS 100 pages Agreement and Plan of Merger and Reorganization by and Among Poseida Therapeutics Inc., Hermes Merger Sub I, Inc., Hermes Merger Sub II, LLC, Vindico Nanobiotechnology, Inc. and Christopher Young as Stockholders’ Representative October 10, 2016
12/34/56
EX-2.1
from DRS 22 pages Asset Contribution Agreement
12/34/56